PT  - JOURNAL ARTICLE
AU  - Kuylen, Elise J.
AU  - Torneri, Andrea
AU  - Willem, Lander
AU  - Libin, Pieter J. K.
AU  - Abrams, Steven
AU  - Coletti, Pietro
AU  - Franco, Nicolas
AU  - Verelst, Frederik
AU  - Beutels, Philippe
AU  - Liesenborgs, Jori
AU  - Hens, Niel
TI  - Different forms of superspreading lead to different outcomes: heterogeneity in infectiousness and contact behavior relevant for the case of SARS-CoV-2
AID  - 10.1101/2022.03.03.22271824
DP  - 2022 Jan 01
TA  - medRxiv
PG  - 2022.03.03.22271824
4099  - http://medrxiv.org/content/early/2022/03/06/2022.03.03.22271824.short
4100  - http://medrxiv.org/content/early/2022/03/06/2022.03.03.22271824.full
AB  - Superspreading events play an important role in the spread of SARS-CoV-2 and several other pathogens. Hence, while the basic reproduction number of the original Wuhan SARS-CoV-2 is estimated to be about 3 for Belgium, there is substantial inter-individual variation in the number of secondary cases each infected individual causes. Multiple factors contribute to the occurrence of superspreading events: heterogeneity in infectiousness and susceptibility, variations in contact behavior, and the environment in which transmission takes place. While superspreading has been included in several infectious disease transmission models, our understanding of the effect that these different forms of superspreading have on the spread of pathogens and the effectiveness of control measures remains limited. To disentangle the effects of infectiousness-related heterogeneity on the one hand and contact-related heterogeneity on the other, we implemented both forms of superspreading in an individual-based model describing the transmission and spread of SARS-CoV-2 in the Belgian population. We considered its impact on viral spread as well as on the effectiveness of social distancing. We found that the effects of superspreading driven by heterogeneity in infectiousness are very different from the effects of superspreading driven by heterogeneity in contact behavior. On the one hand, a higher level of infectiousness-related heterogeneity results in less outbreaks occurring following the introduction of one infected individual. Outbreaks were also slower, with a lower peak which occurred at a later point in time, and a lower herd immunity threshold. Finally, the risk of resurgence of an outbreak following a period of lockdown decreased. On the other hand, when contact-related heterogeneity was high, this also led to smaller final sizes, but caused outbreaks to be more explosive in regard to other aspects (such as higher peaks which occurred earlier, and a higher herd immunity threshold). Finally, the risk of resurgence of an outbreak following a period of lockdown increased. Determining the contribution of both source of heterogeneity is therefore important but left to be explored further.Author summary To investigate the effect of different sources of superspreading on disease dynamics, we implemented superspreading driven by heterogeneity in infectiousness and heterogeneity in contact behavior into an individual-based model for the transmission of SARS-CoV-2 in the Belgian population. We compared the impact of both forms of superspreading in a scenario without interventions as well as in a scenario in which a period of strict social distancing (i.e. a lockdown) is followed by a period of partial release. We found that both forms of superspreading have very different effects. On the one hand, increasing the level of infectiousness-related heterogeneity led to less outbreaks being observed following the introduction of one infected individual in the population. Furthermore, final outbreak sizes decreased, and outbreaks became slower, with lower and later peaks, and a lower herd immunity threshold. Finally, the risk for resurgence of an outbreak following a period of lockdown also decreased. On the other hand, when contact-related heterogeneity was high, this also led to smaller final sizes, but caused outbreaks to be more explosive regarding other aspects (such as higher peaks that occurred earlier). The herd immunity threshold also increased, as did the risk of resurgence of outbreaks.Competing Interest StatementThe authors have declared no competing interest.Funding StatementWe acknowledge funding from the Flemish Government through IBOF (E.J.K., P.B. and N.H.: IBOF.21.027 Descartes project) and from the Research Foundation Flanders (FWO) (S.A. and N.H.: G0G2920N RESTORE project; E.J.K and N.H.: grant agreement R-7861). This work also received funding from the European Research Council (ERC) under the European Union's Horizon 2020 research and innovation program (A.T., P.J.K.L., N.F., F.V., P.B. and N.H.: grant agreement 101003688 EpiPose; P.C. and N.H.: grant agreement 682540 TransMID). Furthermore, L.W. and P.J.K.L. gratefully acknowledge support from the Research Foundation Flanders (FWO) via postdoctoral fellowships 1234620N and 1242021N. P.J.K.L. also acknowledges support from the Research council of the Vrije Universiteit Brussel (OZR-VUB) via grant number OZR3863BOF, and from the Flemish Government through the AI Research Program. Finally, P.B. and N.H. acknowledge funding from the Antwerp Study Center for Infectious Diseases (ASCID) and the Methusalem-Centre of Excellence consortium VAX-IDEA. We used computational resources and services provided by the Flemish Supercomputer Centre (VSC), funded by the FWO and the Flemish Government. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll relevant code and data will be made available upon acceptance of the article.